The Mammary ONcology Assessment of LEE011’s Efficacy and SAfety (MONALEESA-2) conducted trials on postmenopausal HR-positive and HER2-negative advanced breast cancer women who received no previous systemic treatment in 2016. This evidence concerns the gene ERBB2 and breast cancer.